CASE STUDY: Stiris Research Stabilizes Site Performance to Protect a Phase IIa ALS Trial Milestone
Executive Summary
- Therapeutic area: Neurology – Amyotrophic Lateral Sclerosis (ALS)
- Phase: Phase IIa
- Geography: Clinical site within global program
- Challenge: A high-enrolling clinical trial site faced operational strain, resulting in delayed data query resolution, delays in ethics submissions and updates to essential regulatory documentation, and communication bottlenecks. Contracting and budget delays increased operational friction, while internal site misalignment disrupted coordination and impeded timely decision-making ahead of a fixed interim analysis milestone.
- Result: Site performance stabilized and responsiveness restored, enabling on-time delivery of the sponsor’s interim analysis despite significant resourcing constraints.
Challenge
As this Phase IIa clinical trial progressed, early signals from the Principal Investigator indicated emerging institutional resourcing limitations at a high-enrolling site, a scenario familiar in rare disease programs where patient populations are small and operational margins are thin.
The study coordinator was significantly overextended, resulting in operational strain and workflow inefficiencies, including:
- Delays in data query resolution
- Backlog in regulatory documentation updates
- Communication breakdowns across cross-functional study teams
At the same time, unresolved contract and budget adjustments compounded operational friction, common in complex clinical trials requiring rapid scaling of site infrastructure.
Within the site’s structure, the Principal Investigator was also affiliated with a higher-capacity site, creating potential for operational restructuring. However, misalignment across sites delayed decision-making and introduced operational uncertainty. These challenges emerged while a sponsor-mandated interim analysis deadline approached, leaving minimal operational flexibility and increasing the risk of cohort delays, recruitment limitations, and timeline slippage. Risks that carry greater impact especially in rare disease trials.
Solution
As a full-service CRO with deep expertise in clinical trial execution, Stiris executed a targeted site stabilization strategy, integrating site management and operational oversight, to restore site performance and keep the study on track.
- Relationship-Driven Site Engagement
Stiris transitioned from high-volume email communication to direct, structured phone-based interactions, improving clarity and accelerating decision-making. A personalized communication approach was developed based on the study coordinator’s workflow preferences, significantly reducing operational friction.
- Structured Prioritization System
Custom tracking tools were implemented to manage open queries, source documentation updates, and outstanding action items were prioritized collaboratively with the site, enabling the coordinator to focus on critical activities while deferring lower-priority work without impacting study progress.
- On-Site Monitoring & Operational Support
During each Interim Monitoring Visit (IMV), dedicated time was spent addressing complex data issues directly with the site coordinator, improving data clarity and turnaround. In parallel, Stiris provided hands-on administrative and regulatory support, allowing coordinators to focus on patient-facing activities while maintaining inspection-ready documentation.
Results
- Stabilized Site Performance
Targeted engagement and structured operational support restored responsiveness across all site stakeholders and improved overall execution consistency throughout the clinical trial.
- Protected Interim Analysis Timeline
Despite significant site-level constraints, the interim analysis milestone was successfully delivered on schedule without protocol amendments or disruption to recruitment or study execution.
- Strengthened Operational Alignment
Stiris improved coordination across site stakeholders, restoring alignment between operational teams and ensuring continuity in a complex two-site structure.
Sponsor Impact
Stiris Research successfully stabilized a high-risk site in a time-sensitive Phase IIa ALS clinical trial.
Through hands-on operational support and proactive site engagement, Stiris protected critical study milestones, reduced execution risk, and ensured uninterrupted clinical development progress in a rare disease program where timelines were highly constrained.
Key Takeaways
- Relationship-driven communication improves execution more effectively than email escalation
- Structured prioritization reduces coordinator burden and improves responsiveness
- Transparent sponsor communication enables proactive risk mitigation
- Hands-on site support can prevent operational delays and maintain study conduct
- Operational agility is essential in rare disease clinical trials
- Regulatory support and clinical project management must work in sync to protect interim analysis deadlines
Protect Your Critical Trial Milestones
The difference between a delayed milestone and an on-time delivery often comes down to one decision: who you have in your corner.
Stiris Research brings hands-on expertise, deep site-level knowledge and relationships, and operational agility to protect critical trial outcomes. Connect with us before your timelines are at risk. Contact us info@stirisresearch.com